DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment
Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.
This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.
Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.
Guidance raise and buybacks are direct positive catalysts for the stock.
Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.
This explains the negative price reaction despite headline beats.
Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.
This is the key reason for the sharp negative price move after earnings.